RecruitingNCT06922526

Pacemaker-related Tricuspid Regurgitation Progression and Long-term Outcomes

Predictors of Tricuspid Regurgitation Progression and Adverse Outcomes in Different Pacing Modes


Sponsor

Haiyan Wang

Enrollment

200 participants

Start Date

Apr 1, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

Tricuspid regurgitation (TR) is a common complication following cardiac implantable electronic device (CIED) implantation, with severe TR being associated with increased rates of heart failure hospitalization and all-cause mortality, significantly impairing patients' quality of life. With technological advancements, physiological pacing modalities have demonstrated superior clinical efficacy and safety profiles compared to conventional pacing methods. This study aims to evaluate predictors of adverse outcomes and TR progression in CIED recipients under different pacing modalities, thereby providing clinical guidance for high-risk patients.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Adult patients
  • Patients with an implantable electronic heart device (CIEDs)
  • The patient underwent pacemaker implantation at Qianfoshan Hospital between 2015 and 2025

Exclusion Criteria3

  • Patients with severe tricuspid regurgitation or those who have undergone tricuspid valve surgery or interventional treatment prior to pacemaker implantation
  • Patients with severe valvular heart disease, congenital heart disease, or arrhythmias
  • Patients with single-chamber pacemakers or poor images

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEPacemaker implantation

Pacemaker implantation methods include right ventricular pacing, biventricular pacing, conduction system pacing


Locations(1)

The First Affiliated Hospital of Shandong First Medical University

Jinan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06922526


Related Trials